Want to see HK:0401 full AI Analyst Report?
0401 Stock Chart & Stats
HK$0.09
>-HK$0.01(-5.66%)
At close: 4:00 PM EST
HK$0.09
>-HK$0.01(-5.66%)
Day’s Range― - ―
52-Week RangeHK$0.05 - HK$0.21
Previous CloseN/A
Volume1.34M
Average Volume (3M)589.99K
Market Cap
HK$134.31M
Enterprise ValueHK$59.94
Total Cash (Recent Filing)HK$33.03M
Total Debt (Recent Filing)HK$12.21M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,128,615,700
10 Day Avg. Volume1,113,336
30 Day Avg. Volume589,992
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)1.08
Price to Sales (P/S)0.55
P/FCF Ratio-10.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageLow leverage and higher equity in 2026 provide balance-sheet stability and durable financial flexibility. This reduces refinancing pressure and supports working capital needs during operating swings, giving the company capacity to fund operations or selective investments without immediate external financing.
Historical Cash GenerationThe company demonstrated an ability to convert operations into cash in 2023–2025, indicating the business model can generate internal funds under normal conditions. That historical cash-generation track record is a durable asset for funding operations, servicing debt, or supporting recovery when margins improve.
Revenue ResilienceA return to modest revenue growth in 2026 suggests underlying demand stability in its medical distribution activities. Stable top-line trends create a base for operating leverage and potential margin recovery if cost structures are tightened, supporting a mid-term path toward restored profitability.
Bears Say
Inconsistent ProfitabilityPersistent net losses and negative returns on equity undermine capital accumulation and internal funding ability. Ongoing unprofitability erodes shareholder equity over time, constrains reinvestment capacity, and raises the structural difficulty of rebuilding sustainable margins without clear operational changes.
2026 Cash-Flow ReversalThe sharp swing to negative operating and free cash flow in 2026 materially reduces financial flexibility and increases reliance on external funding or cost cuts. If this cash-flow weakness persists, it can force asset sales, curb investments, or pressure liquidity, creating a multi-month structural risk to operations.
Margin DeteriorationMeaningful compression in gross margin and worsening operating losses reduce earnings leverage and make a return to sustained profitability harder. Lower margins increase sensitivity to cost or pricing pressures and can permanently impair the company’s ability to convert modest revenue growth into positive net income.
Wanjia Group Holdings Ltd. News
0401 FAQ
What was Wanjia Group Holdings Ltd.’s price range in the past 12 months?
Wanjia Group Holdings Ltd. lowest stock price was HK$0.05 and its highest was HK$0.21 in the past 12 months.
What is Wanjia Group Holdings Ltd.’s market cap?
Wanjia Group Holdings Ltd.’s market cap is HK$134.31M.
When is Wanjia Group Holdings Ltd.’s upcoming earnings report date?
Wanjia Group Holdings Ltd.’s upcoming earnings report date is Nov 25, 2026 which is in 110 days.
How were Wanjia Group Holdings Ltd.’s earnings last quarter?
Wanjia Group Holdings Ltd. released its earnings results on Jun 29, 2026. The company reported -HK$0.016 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Wanjia Group Holdings Ltd. overvalued?
According to Wall Street analysts Wanjia Group Holdings Ltd.’s price is currently Overvalued.
Does Wanjia Group Holdings Ltd. pay dividends?
Wanjia Group Holdings Ltd. does not currently pay dividends.
What is Wanjia Group Holdings Ltd.’s EPS estimate?
Wanjia Group Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wanjia Group Holdings Ltd. have?
Wanjia Group Holdings Ltd. has 1,128,615,700 shares outstanding.
What happened to Wanjia Group Holdings Ltd.’s price movement after its last earnings report?
Wanjia Group Holdings Ltd. reported an EPS of -HK$0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Wanjia Group Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:0401
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wanjia Group Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
24.11%
Trailing 12-Months
Company Description
Wanjia Group Holdings Ltd.
Wanjia Group Holdings Limited operates as an investment holding company, primarily engaged in the wholesale and distribution of pharmaceutical products across mainland China and Hong Kong. The firm also offers hemodialysis treatment and associated consultancy services. Its pharmaceutical goods are supplied to a diverse client base within Fujian province, including hospitals, various healthcare institutions, pharmaceutical retail chains, independent pharmacies, outpatient departments of community hospitals, healthcare service stations, and clinics. Established in 2004, the company is headquartered in Kowloon, Hong Kong.
Technical Analysis
China Health Group
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Medlive Technology Co., Ltd.
―
Charmacy Pharmaceutical Co., Ltd. Class H
―